TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

OMONTYS

PEGINESATIDE ACETATE
Approved 2012-03-27
1
Indication
--
Phase 3 Trials
13
Years on Market

Details

Status
Discontinued
First Approved
2012-03-27
Routes
INTRAVENOUS, SUBCUTANEOUS
Dosage Forms
SOLUTION

Companies

Active Ingredient: PEGINESATIDE ACETATE

OMONTYS Approval History

Loading approval history...

What OMONTYS Treats

1 FDA approvals

Originally approved for its first indication in 2012 .

  • Other (1)
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

OMONTYS FDA Label Details

Pro

OMONTYS Patents & Exclusivity

Latest Patent: Jun 2026

Patents (32 active)

US7550433 Expires Jun 2, 2026
US7919461 Expires Jun 2, 2026
+ 22 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.